Is the diagnosis latent or patent?

Tamler, Ronald
March 2008
Endocrine Today;3/10/2008, Vol. 6 Issue 4, p18
Case Study
The article presents a case study of a man who came to the office of Dr. Ronald Tamler for he was unhappy due to his glycemic control. It notes that a year before, he was diagnosed with type 2 diabetes and probably had diabetes in 2004 when he was hospitalized for hyperglycemia. He has been experiencing polydipsia and polyuria and lost 40 pounds. It was found that the patient has dyslipidemia and poorly controlled diabetes. His weight loss is due to an insulin-deficient state. An autoimmune component is suggested for his history of hypothyroidism.


Related Articles

  • The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31 

    Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...

  • A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus. Howlett, H.C.S.; Bailey, C.J. // Drug Safety;Jun1999, Vol. 20 Issue 6, p489 

    Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial hyperglycaemia by about 25% in more than 90% of patients when either given alone or coadministered with other therapies...

  • Hemodynamic Effects of Acute Hyperglycemia in Type 2 Diabetic Patients. Marfella, Raffaele; Nappo, Francesco; De Angelis, Lorenita; Paolisso, Giuseppe; Tagliamonte, Maria Rosaria; Giugliano, Dario // Diabetes Care;May2000, Vol. 23 Issue 5, p658 

    Focuses on a study which evaluated the hemodynamic effects of acute hyperglycemia in type 2 diabetic patients and to see whether these effects are related to changes in nitric oxide availability. Research design and methods; Results; Conclusions.

  • The Efficacy of Acarbose in the Treatment of Patients with non-Insulin-dependent Diabetes Mellitus. Chiasson, Jean Louis; Josse, Robert G.; Hunt, John A.; Palmason, Carol; Rodger, N. Wilson; Ross, Stuart A.; Ryan, Edmond A.; Tan, Meng H.; Wolever., Thomas M.S. // Annals of Internal Medicine;12/15/94, Vol. 121 Issue 12, p928 

    Presents a study which evaluated the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycemic control in patients with non-insulin-dependent diabetes mellitus. Alternative approach to the problem of postprandial hyperglycemia; Methods used in the study; Results and...

  • Morning Hyperglycemic Excursions. Monnier, Louis; Rabasa-Lhoret, Remy; Lapinski, Helene; Caubel, Cecile; Avignon, Antoine; Boniface, Helene; Colette, Claude // Diabetes Care;Apr2002, Vol. 25 Issue 4, p737 

    Presents a study that determined whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. Protocol of the study and analytical procedures; Comparison of plasma glucose and insulin concentrations...

  • Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding. Basu, Ananda; Basu, Rita; Shah, Pankaj; Vella, Adrian; Johnson, C. Michael; Jensen, Michael; Nair, K. Sreekumaran; Schwenk, W. Frederick; Rizza, Robert A. // Diabetes;Jun2001, Vol. 50 Issue 6, p1351 

    Focuses on the effects of diabetes on the splanchnic uptake of glucose. Decrease in the contribution of extracellular pathway to hepatic glycogen synthesis; Role of abnormal hepatic and muscle glucose metabolism on postprandial hyperglycemia; Characterization of type 2 diabetes.

  • Managing hyperglycemia in Type 2 diabetes: Here's how. Fernandez, Julio // Drug Topics;9/18/2006, Vol. 150 Issue 18, p25 

    The article presents an instructional material on the management of hyperglycemia in patients with non-insulin-dependent diabetes.

  • Erratum to: Canagliflozin: First Global Approval. Elkinson, Shelley; Scott, Lesley J. // Drugs;Nov2013, Vol. 73 Issue 16, p1847 

    A correction to the article "Canagliflozin: First Global Approval" that was published in the October 2013 issue is presented.

  • Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections Froma Diabetes Care Editors' Expert Forum. GIUGLIANO, DARIO; ESPOSITO, KATHERINE // Diabetes Care;Nov2013, Vol. 36 Issue 11, pe192 

    A letter to the editor is presented in response to the article "Personalized management of hyperglycemia in type 2 diabetes: reflections from a "Diabetes Care" Editors' Expert Forum," by I. Raz and colleagues in the 2013 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics